mRNA COVID-19 vaccines
Showing 1 - 25 of >10,000
COVID-19 Trial (NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg))
Not yet recruiting
- COVID-19
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
- Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- (no location specified)
Aug 4, 2023
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection Trial (Novavax COVID-19 vaccine (2023-2024 formula XBB containing),
Not yet recruiting
- COVID-19
- +4 more
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing)
- Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- (no location specified)
Sep 29, 2023
SARS-CoV-2 Infection Trial in Groningen, Utrecht, Auckland (VLA2001)
Active, not recruiting
- SARS-CoV-2 Infection
- VLA2001
-
Groningen, Netherlands
- +3 more
Jan 17, 2023
SARS-CoV-2 Trial (CV0701 Bivalent High dose, CV0701 Bivalent Medium dose, CV0701 Bivalent Low dose)
Not yet recruiting
- SARS-CoV-2
- CV0701 Bivalent High dose
- +4 more
- (no location specified)
Jul 24, 2023
Pain, Quality of Life, Injection Site Reaction Trial in Baltimore, Durham, Cincinnati (mRNA COVID-19, IIV4, Placebo)
Suspended
- Pain
- +3 more
- mRNA COVID-19
- +2 more
-
Baltimore, Maryland
- +2 more
Jun 21, 2022
Fever After Vaccination, Fever, Seizures Fever Trial in United States (Pfizer-BioNTech COVID-19 Vaccine, Routine Childhood
Not yet recruiting
- Fever After Vaccination
- +2 more
- Pfizer-BioNTech COVID-19 Vaccine
- Routine Childhood Vaccinations
-
Oakland, California
- +4 more
Sep 8, 2023
Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)
Not yet recruiting
- Immunogenicity
- Safety
- Phase II:SWIM816;SARS-Cov-2;
- +3 more
- (no location specified)
Jun 18, 2023
COVID-19 Vaccines Using Information From California State
Not yet recruiting
- SARS-CoV-2
- +2 more
- Pfizer-BioNTech COVID-19 bivalent mRNA vaccine
- (no location specified)
May 23, 2023
Immune Response, Safety Trial in Incheon (bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine, quadrivalent influenza
Active, not recruiting
- Immune Response
- Safety
- bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
- quadrivalent influenza vaccine
-
Incheon, Seo-gu, Korea, Republic ofInternational St. Mary's hospital
Jul 28, 2023
COVID-19, SARS-CoV-2 Infection Trial in Morelia (Recombinant COVID-19 variant Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell),
Not yet recruiting
- COVID-19
- SARS-CoV-2 Infection
- Recombinant COVID-19 variant Vaccine (Sf9 Cell)
- +3 more
-
Morelia, Michoacán De Ocampo, MexicoClínica de Enfermedades Crónicas y de Procedimientos Especiales,
Jul 18, 2022
COVID-19 Trial in Wuhan (Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For
Recruiting
- COVID-19
- Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation
- +2 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Jun 1, 2023
COVID-19 Trial in Bizerte, Ariana, Tunis (CoronaVac/CoronaVac, CoronaVac/BNT162b2)
Completed
- COVID-19
- CoronaVac/CoronaVac
- CoronaVac/BNT162b2
-
Bizerte, Mateur, Tunisia
- +4 more
Jan 4, 2023
Patients Given Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine
Recruiting
- Influenza, Human
- COVID-19
- Comirnaty
- Quadrivalent Influenza Vaccine
-
New York, New YorkPfizer
May 11, 2023
COVID-19 Trial in United States (NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant)
Active, not recruiting
- COVID-19
- NVX-CoV2373
- SARS-CoV-2 rS antigen/Matrix-M Adjuvant
-
Austin, Texas
- +4 more
May 16, 2023
COVID-19, SARS-CoV-2 Infection Trial (SCTV01E-2, SCTV01E)
Not yet recruiting
- COVID-19
- SARS-CoV-2 Infection
- SCTV01E-2
- SCTV01E
- (no location specified)
Jul 4, 2023
HIV, Organ Transplantation, Lymphoma, Non-Hodgkin Trial in Melbourne (Pfizer Bivalent COVID-19 Vaccine, Moderna Bivalent mRNA
Recruiting
- HIV
- +5 more
- Pfizer Bivalent COVID-19 Vaccine
- Moderna Bivalent mRNA vaccine
-
Melbourne, Victoria, AustraliaAlfred Health
Jan 31, 2023
COVID-19, SARS-CoV-2 Infection Trial in Iloilo City (Recombinant COVID-19 Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell),
Recruiting
- COVID-19
- SARS-CoV-2 Infection
- Recombinant COVID-19 Vaccine (Sf9 Cell)
- COVID-19 Vaccine (Vero Cell), Inactivated
-
Iloilo City, PhilippinesIloilo Doctors Hospital
Jul 18, 2022
COVID-19, COVID-19 Immunisation Trial in Decatur, Bethesda, Seattle (mRNA-1273)
Completed
- COVID-19
- COVID-19 Immunisation
- mRNA-1273
-
Decatur, Georgia
- +2 more
Jan 26, 2023
COVID-19 Trial in Jakarta (ABO1009-DP, ABO-CoV.617.2, Placebo)
Recruiting
- COVID-19
- ABO1009-DP
- +2 more
-
Jakarta, Indonesia
- +1 more
Jul 25, 2022
COVID-19 Trial (Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine
Not yet recruiting
- COVID-19
- Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)
- +2 more
- (no location specified)
Jul 5, 2022
First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney
Active, not recruiting
- Kidney Diseases
- +5 more
- Booster dose of mRNA vaccine
-
Praha, CzechiaInstitute for Clinical and Experimental Medicine
Aug 2, 2022
Chronic Liver Disease Trial in Hong Kong (BNT162b2, CoronaVac, AZD1222)
Recruiting
- Chronic Liver Disease
- BNT162b2
- +2 more
-
Hong Kong, Hong KongHumanity & Health Medical Group Limited
Aug 1, 2022
SafeTy and Efficacy of Preventative CoVID Vaccines
Active, not recruiting
- COVID-19 Virus Infection
- Vaccine Response
- mRNA Vaccines or Viral vector-based vaccines for COVID
-
Toronto, Ontario, CanadaUniversity Health Network
May 19, 2022
COVID-19, COVID-19 Immunisation Trial in United States (mRNA-1273, mRNA-1273.351)
Active, not recruiting
- COVID-19
- COVID-19 Immunisation
- mRNA-1273
- mRNA-1273.351
-
Decatur, Georgia
- +3 more
Aug 11, 2022
mRNA Covid-19 Vaccines on Cancer Patients:Observational Study.
Recruiting
- Cancer
- +2 more
- Serum collection, adverse events collection
-
Cremona, Lombardia, ItalyUO Oncologia, ASST di Cremona
Jul 22, 2021